Hormones and Agents Affecting Hormonal Mechanism: Calcium Regulating Agents
OALEN1 “Alendronate tablet” 70 mg/tab
OFOSA2 “Fosamax Plus tablet” 70 mg/tab
適應症：停經婦女骨質疏鬆症之治療，治療男性骨質疏鬆症。
Usual dose: 70 mg qw or 10 mg qd.
Contraindication:
Esophageal abnormalities (stricture or achalasia) which delay esophageal emptying, hypocalcemia.
Adverse effect:
Common: abdominal pain, constipation, diarrhea, flatulence, indigestion, vomiting, headache.
Serious: skin reaction extreme, duodenal ulcer disease, esophageal erosions, with bleeding, esophageal perforation, esophageal stricture, esophagitis, gastric ulcer, ulcerative pharyngitis, acute, ulcer of esophagus, hypersensitivity reaction, arthralgia, aseptic necrosis of bone of the jaw, bone pain, myalgia.
健保使用規範：
(1) 限用於停經後婦女（alendronate、zoledronate、denosumab及risedronate亦可使用於男性）因骨質疏鬆症（須經DXA 檢測BMD之T score≦ -2.5SD）引起脊椎或髖部骨折，或因骨質疏少症(osteopenia)(經DXA檢測BMD之-2.5SD <T score <-1.0SD)引起脊椎或髖部2處或2次(含)以上之骨折。(101/5/1、102/8/1、103/10/1、104/8/1)
(2)治療時，一次限用一項藥物，不得併用其他骨質疏鬆症治療藥物。
(3)使用雙磷酸鹽類藥物，須先檢測病患之血清creatinine濃度，符合該項藥物仿單之建議規定。